Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
News|Articles|October 1, 2024
Adaptive Radiotherapy Modality Appears Safe, Feasible in High-Grade Glioma
Author(s)Russ Conroy
Fact checked by: Ariana Pelosci
UNITED is the first trial to assess MR-guided weekly adaptive on-line and real-time radiotherapy with clinical target volume margin reductions.
Advertisement
Advertisement
Weekly on-line MR-Linac (MRL) adaptive radiotherapy plus concurrent temozolomide (Temodar) appeared safe and feasible while significantly reducing the clinical target volume (CTV) margins and normal brain tissue exposure among patients with high-grade glioma, according to findings from the phase 2 UNITED trial (NCT04726397) presented at the
Related to this article
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Advertisement
Advertisement